Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE)

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Droppa, Michal ^a   Tschernow, Dimitri ^a   Müller, Karin A L ^a   Tavlaki, Elli ^a   Karathanos, Athanasios ^a   Stimpfle, Fabian ^a   Schaeffeler, Elke ^b   Schwab, Matthias ^a,b   Tolios, Alexander ^c   Siller Matula, Jolanta M ^d   Gawaz, Meinrad ^a   Geisler, Tobias ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH ON TREATMENT PLATELET REACTIVITY; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PREDICTION; RISK ASSESSMENT; THERAPY EFFECT; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; ADVERSE EFFECTS; BLOOD; BLOOD CLOTTING PARAMETERS; DRUG EFFECTS; KIDNEY FUNCTION TEST; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; POSTOPERATIVE COMPLICATIONS; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; RISK FACTOR; STENT; THROMBOSIS; TREATMENT OUTCOME;

AGE FACTORS; AGED; BODY MASS INDEX; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POSTOPERATIVE COMPLICATIONS; REGRESSION ANALYSIS; RISK FACTORS; ROC CURVE; STENTS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84925832825     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121620     Document Type: Article

References (47)

1. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010; 31: 2501-2555. doi: 10.1093/eurheartj/ehq277 PMID: 20802248
2. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107: 2908-2913. PMID: 12796140
3. Müller I, Besta F, Schulz C, Massberg S, Schönig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003; 89: 783-787. PMID: 12719773
4. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005; 45: 246-251. PMID: 15653023
5. Tantry US, Bonello L, Aradi D, Price MJ, Jeong Y-H, Angiolillo DJ, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013; 62: 2261-2273. doi: 10.1016/j.jacc.2013.07.101 PMID: 24076493
6. Price MJ, Berger PB, Teirstein PS, Tanguay J-F, Angiolillo DJ, Spriggs D, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA J Am Med Assoc. 2011; 305: 1097-1105.
7. Collet J-P, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012; 367: 2100-2109. doi: 10.1056/NEJMoa1209979 PMID: 23121439
8. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 2012; 59: 2159-2164. doi: 10.1016/j.jacc.2012.02.026 PMID: 22520250
9. Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, Dietz K, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost JTH. 2008; 6: 54-61. PMID: 17949474
10. Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost JTH. 2012; 10: 529-542. doi: 10.1111/j.1538-7836.2012.04639.x PMID: 22260716
11. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005; 111: 2560-2564. PMID: 15809367
12. Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006; 27: 2420-2425. PMID: 17005534
13. Spiliopoulos S, Pastromas G, Katsanos K, Kitrou P, Karnabatidis D, Siablis D. Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity. J Am Coll Cardiol. 2013; 61: 2428-2434. doi: 10.1016/j.jacc.2013.03.036 PMID: 23602777
14. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol. 2005; 46: 1820-1826. PMID: 16286165
15. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol. 2005; 46: 1827-1832. PMID: 16286166
16. Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schömig A, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost. 2008; 99: 121-126. doi: 10.1160/TH07-07-0478 PMID: 18217143
17. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012; 33: 2551-2567. doi: 10.1093/eurheartj/ehs184 PMID: 22922414
18. Neumann FJ, Gawaz M, Ott I, May A, Mössmer G, Schömig A. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol. 1996; 27: 15-21. PMID: 8522689
19. Gawaz M, Neumann FJ, Ott I, May A, Rüdiger S, Schömig A. Role of activation-dependent platelet membrane glycoproteins in development of subacute occlusive coronary stent thrombosis. Coron Artery Dis. 1997; 8: 121-128. PMID: 9237020
20. Bucher HC, Hengstler P, Schindler C, Guyatt GH. Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials. BMJ. 2000; 321: 73-77. PMID: 10884254
21. Jeremias A, Kaul S, Rosengart TK, Gruberg L, Brown DL. The impact of revascularization on mortality in patients with nonacute coronary artery disease. Am J Med. 2009; 122: 152-161. doi: 10.1016/j.amjmed.2008.07.027 PMID: 19185092
22. Wenaweser P, Dörffler-Melly J, Imboden K, Windecker S, Togni M, Meier B, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol. 2005; 45: 1748-1752. PMID: 15936599
23. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost JTH. 2006; 4: 542-549. PMID: 16371119
24. Hulot J-S, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-offunction polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006; 108: 2244-2247. PMID: 16772608
25. Suh J-W, Koo B-K, Zhang S-Y, Park K-W, Cho J-Y, Jang I-J, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ Can Med Assoc J J Assoc Medicale Can. 2006; 174: 1715-1722.
26. Geisler T, Anders N, Paterok M, Langer H, Stellos K, Lindemann S, et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care. 2007; 30: 372-374. PMID: 17259513
27. Geisler T, Mueller K, Aichele S, Bigalke B, Stellos K, Htun P, et al. Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions. Clin Res Cardiol Off J Ger Card Soc. 2010; 99: 743-752. doi: 10.1007/s00392-011-0370-8 PMID: 21960419
28. Htun P, Fateh-Moghadam S, Bischofs C, Banya W, Müller K, Bigalke B, et al. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol JASN. 2011; 22: 627-633. doi: 10.1681/ASN.2010020220 PMID: 21273381
29. Morel O, El Ghannudi S, Jesel L, Radulescu B, Meyer N, Wiesel M-L, et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol. 2011; 57: 399-408. doi: 10.1016/j.jacc.2010.09.032 PMID: 21251579
30. Cuisset T, Quilici J, Grosdidier C, Fourcade L, Gaborit B, Pankert M, et al. Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. Am J Cardiol. 2011; 108: 1411-1416. doi: 10.1016/j.amjcard.2011.06.060 PMID: 21872198
31. Silvain J, Cayla G, Hulot J-S, Finzi J, Kerneis M, O'Connor SA, et al. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. Eur Heart J. 2012; 33: 1241-1249. doi: 10.1093/eurheartj/ehr407 PMID: 22067090
32. Angiolillo DJ, Fernández-Ortiz A, Bernardo E, Barrera Ramírez C, Sabaté M, Fernandez C, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol. 2004; 16: 169-174. PMID: 15152138
33. Bonello-Palot N, Armero S, Paganelli F, Mancini J, De Labriolle A, Bonello C, et al. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2009; 104: 1511-1515. doi: 10.1016/j.amjcard.2009.07.015 PMID: 19932784
34. Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther. 1999; 37: 8-19. PMID: 10027478
35. Marcucci R, Gori AM, Paniccia R, Giglioli C, Buonamici P, Antoniucci D, et al. Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. Atherosclerosis. 2007; 195: e217-e223. PMID: 17555759
36. Peterson ED, Dai D, DeLong ER, Brennan JM, Singh M, Rao SV, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol. 2010; 55: 1923-1932. doi: 10.1016/j.jacc.2010.02.005 PMID: 20430263
37. De Mulder M, Gitt A, van Domburg R, Hochadel M, Seabra-Gomes R, Serruys PW, et al. EuroHeart score for the evaluation of in-hospital mortality in patients undergoing percutaneous coronary intervention. Eur Heart J. 2011; 32: 1398-1408. doi: 10.1093/eurheartj/ehr034 PMID: 21345854
38. Touchette MA, Slaughter RL. The effect of renal failure on hepatic drug clearance. DICP Ann Pharmacother. 1991; 25: 1214-1224.
39. Leblond F, Guévin C, Demers C, Pellerin I, Gascon-Barré M, Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol JASN. 2001; 12: 326-332. PMID: 11158222
40. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010; 122: 1056-1067. doi: 10.1161/CIRCULATIONAHA.109.933796 PMID: 20805430
41. Chung I, Lip GYH. Platelets and heart failure. Eur Heart J. 2006; 27: 2623-2631. PMID: 17028108
42. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-2015. PMID: 17982182
43. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045-1057. doi: 10.1056/NEJMoa0904327 PMID: 19717846
44. Reny J-L, Berdagué P, Poncet A, Barazer I, Nolli S, Fabbro-Peray P, et al. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation. 2012; 125: 3201-3210. doi: 10.1161/CIRCULATIONAHA.111.085464 PMID: 22615340
45. Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, Goodman SG, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA J Am Med Assoc. 2012; 308: 1785-1794.
46. Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366: 9-19. doi: 10.1056/NEJMoa1112277 PMID: 22077192
47. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012; 366: 1404-1413. doi: 10.1056/NEJMoa1200933 PMID: 22443427